Clinical Trial

A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This Phase III study is intended to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy (PSP). Eligible participants will be randomized to receive either NIO752 or placebo followed by an open-label extension.
Protocol Amendment History 5 changes
notable Trial sites expanded: 24 -> 42 locations 2026-07-30
notable Trial sites expanded: 19 -> 24 locations 2026-06-24
notable Trial sites expanded: 6 -> 19 locations 2026-06-19
notable Trial sites expanded: 3 -> 6 locations 2026-05-28
critical Recruitment opened 2026-05-07
Trial Details
NCT Number NCT07498426
Lead Sponsor Novartis Pharmaceuticals
Conditions Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Enrollment 300 participants
Start Date 2026-06-03
Primary Completion 2029-07-20 (estimated)
Study Completion 2031-07-18 (estimated)
Updated on ClinicalTrials.gov 2026-07-29